NCT05899829

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating the Effect of Rifampin (Part 1) and Rabeprazole (Part 2) on the Pharmacokinetics of a Single Dose of Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Bellus Health Inc. - a GSK company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.

Conditions

• Cough
• Healthy

Interventions

Type	Name	Description
DRUG	Camlipixant	Camlipixant will be administered
DRUG	Rabeprazole	Rabeprazole will be administered
DRUG	Rifampin	Rifampin will be administered.

Timeline

• Start date: 2023-06-21
• Primary completion: 2023-08-08
• Completion: 2023-08-08
• First posted: 2023-06-12
• Last updated: 2024-12-04
• Results posted: 2024-12-04

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study